GLP1R and steatosis: Pharmacologic approaches are also advancing: pioglitazone has shown efficacy in improving steatohepatitis (249); incretin-based therapies such as liraglutide and semaglutide significantly improve steatosis, inflammation, and fibrosis (250, 251); and the dual GLP-1/GIP receptor agonist tirzepatide has demonstrated marked reduction in hepatic fat content and MASH resolution (203).